CC
SBBP

Centiva Capital’s Strongbridge Biopharma plc. SBBP Stock Holding History

Centiva Capital’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-15,865
Closed -$95K – 213
2018
Q2 		$95K Buy
+15,865
New +$116K 0.02% 85

Other funds holding SBBP

CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HCS
Harvest Capital Strategies San Francisco, California $73.7M AUM 7.47% 1-Year Est. Return

Centiva Capital's SBBP Position: Q3 2018 in Review

Centiva Capital sold out of Strongbridge Biopharma plc. (SBBP) in Q3 2018, closing a stake of 15,865 shares — an estimated $95K sold.

Centiva Capital first reported a position in SBBP in Q2 2018 and held it in 1 quarter. The position peaked at $95K in Q2 2018. 49 funds tracked by Wall St. Rank hold SBBP as of Q3 2018.

  • Centiva Capital reported no remaining Strongbridge Biopharma plc. position as of Q3 2018 after selling out during the quarter.
  • Centiva Capital sold 15,865 Strongbridge Biopharma plc. shares in Q3 2018, an estimated $95K.
  • Centiva Capital first reported a position in Strongbridge Biopharma plc. in Q2 2018 and held it in 1 quarter.
  • Centiva Capital's Strongbridge Biopharma plc. position peaked at $95K in Q2 2018.
  • 49 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q3 2018.

Based on Centiva Capital's 13F filing for Q3 2018, filed 14 Nov 2018.